The Bile Acid Receptor pipeline drugs market research report outlays comprehensive information on the Bile Acid Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Bile Acid Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Gastrointestinal, Metabolic Disorders, Undisclosed, and Cardiovascular which include the indications Metabolic Dysfunction-Associated Steatohepatitis (MASH), Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Type 2 Diabetes, Obesity, Unspecified, Hypertension, and Portal Hypertension. It also reviews key players involved in Bile Acid Receptor targeted therapeutics development with respective active and dormant or discontinued products.
The Bile Acid Receptor pipeline targets constitutes close to 26 molecules. Out of which, approximately 22 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase II, Phase I, and Preclinical stages are 1, 12, 4, and 5 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 1, and 3 molecule.
Bile Acid Receptor overview
Bile acid receptor, also called Farnesoid X receptor, is a nuclear receptor that controls many metabolic pathways. It regulates bile acid synthesis, conjugation, and transport. On its activation by bile acids, FXR regulates bile acid synthesis, conjugation, and transport, as well as various aspects of lipid and glucose metabolism.
For a complete picture of Bile Acid Receptor’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
